Email Alerts


First Name:
Last Name:
Email:
Contact Type:
	Email me company news as it is released

	By checking above you consent to Pieris Pharmaceuticals GmbH sending you email alerts, including via Pieris Pharmaceuticals, Inc. (located in the United States), and processing your personal data for this purpose so long as you don’t withdraw consent. For European Union residents, please note that your personal data will be sent directly to the United States, where the level of data protection is lower than the level of data protection in the European Union. You can withdraw consent at anytime. Further information on data processing can found in our privacy policy

Pieris Drug Pipeline

Pieris pipeline includes multiple fully proprietary as well as partnered programs in a number of different therapeutic areas. Our most advanced Anticalin program PRS-080 (hepcidin antagonist to treat anemia), our advanced respiratory program PRS-060 (1st-in-class inhaled IL4Ra antagonist to treat asthma) and several of our immuno-oncology (IO) multispecific programs (PRS-300 series), led by PRS-343 (a HER2/4-1BB bispecific), are examples of our fully proprietary programs. As we continue to build our IO and Respiratory franchises, we aim to ultimately develop Pieris into a fully-integrated pharmaceutical company by retaining commercial rights to several of these programs in major markets. For this purpose, we are also joining forces with other pharmaceutical companies, as exemplified by our strategic co-development IO alliance with Servier, with PRS-332 (PD1-based dual checkpoint inhibitor) as the lead program of this collaboration, to which we retain full US rights.

For more information about our pipeline, click here.